Ratings by Credit Suisse (Martin Auster)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 4/18/2023 | Prometheus Biosciences Inc | RXDX | Downgrade | Neutral (Outperform) |
114.01 (199.92) |
75.35% | Details | |
| 3/1/2023 | Prometheus Biosciences Inc | RXDX | Maintain | Outperform (N/A) |
|
Details | ||
| 1/4/2023 | Prometheus Biosciences Inc | RXDX | Maintain | Outperform (N/A) |
|
Details | ||
| 12/7/2022 | Prometheus Biosciences Inc | RXDX | Maintain | Outperform (N/A) |
|
Details | ||
| 12/7/2022 | Prometheus Biosciences Inc | RXDX | Maintain | Outperform (N/A) |
|
Details | ||
| 11/3/2022 | Ultragenyx Pharma | RARE | Maintain | Outperform (N/A) |
|
Details | ||
| 8/5/2022 | Intellia Therapeutics | NTLA | Maintain | Outperform (N/A) |
|
Details | ||
| 6/6/2022 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Outperform (N/A) |
|
Details | ||
| 6/1/2022 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Outperform (N/A) |
|
Details | ||
| 5/6/2022 | Intellia Therapeutics | NTLA | Maintain | Outperform (N/A) |
|
Details | ||
| 3/16/2022 | Ultragenyx Pharma | RARE | Upgrade | Outperform (Neutral) |
62.20 (25.83) |
-58.47% | Details | |
| 3/10/2022 | Prometheus Biosciences Inc | RXDX | Maintain | Outperform (N/A) |
|
Details | ||
| 12/14/2021 | Arena Pharma | ARNA | Downgrade | Neutral (Outperform) |
49.94 (99.98) |
100.2% | Details | |
| 11/16/2021 | Spruce Biosciences, Inc. | SPRB | Maintain | Outperform (N/A) |
|
Details | ||
| 10/28/2021 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Outperform (N/A) |
|
Details | ||
| 9/28/2021 | Arena Pharma | ARNA | Maintain | Outperform (N/A) |
|
Details | ||
| 4/14/2021 | Flexion Therapeutics | FLXN | Maintain | Outperform (N/A) |
|
Details | ||
| 4/13/2021 | Arena Pharma | ARNA | Maintain | Outperform (N/A) |
|
Details | ||
| 4/6/2021 | Prometheus Biosciences Inc | RXDX | New Coverage | Outperform (N/A) |
18.18 (199.92) |
999.67% | Details | |
| 4/5/2021 | Acceleron Pharma | XLRN | Maintain | Outperform (N/A) |
|
Details | ||
| 3/23/2021 | Entasis Therapeutics | ETTX | Maintain | Outperform (N/A) |
|
Details | ||
| 3/23/2021 | Spruce Biosciences, Inc. | SPRB | Maintain | Outperform (N/A) |
|
Details | ||
| 3/22/2021 | Fulcrum Therapeutics | FULC | New Coverage | Outperform (N/A) |
11.58 (3.83) |
-66.93% | Details | |
| 3/16/2021 | Solid Biosciences | SLDB | Maintain | Neutral (N/A) |
|
Details | ||
| 3/16/2021 | Galecto | GLTO | Maintain | Outperform (N/A) |
|
Details | ||
| 3/11/2021 | Flexion Therapeutics | FLXN | Maintain | Outperform (N/A) |
|
Details | ||
| 3/10/2021 | Stoke Therapeutics | STOK | Maintain | Outperform (Outperform) |
|
Details | ||
| 3/2/2021 | Sarepta Therapeutics | SRPT | Maintain | Neutral (N/A) |
|
Details | ||
| 2/22/2021 | United Therapeutics Corp. | UTHR | Maintain | Outperform (N/A) |
|
Details | ||
| 2/11/2021 | ALX Oncology | ALXO | Maintain | Outperform (N/A) |
|
Details | ||
| 2/4/2021 | Alexion Pharmaceuticals | ALXN | Maintain | Neutral (N/A) |
|
Details | ||
| 1/25/2021 | Ultragenyx Pharma | RARE | Maintain | Neutral (N/A) |
|
Details | ||
| 1/19/2021 | Insmed | INSM | Maintain | Outperform (N/A) |
|
Details | ||
| 1/11/2021 | PTC Therapeutics | PTCT | Maintain | Neutral (N/A) |
|
Details | ||
| 1/11/2021 | Scholar Rock | SRRK | New Coverage | Outperform (N/A) |
47.20 (56.50) |
19.7% | Details | |
| 1/8/2021 | Sarepta Therapeutics | SRPT | Maintain | Neutral (N/A) |
|
Details | ||
| 1/8/2021 | Solid Biosciences | SLDB | Upgrade | Neutral (Underperform) |
7.08 (9.30) |
31.36% | Details | |
| 12/14/2020 | Sarepta Therapeutics | SRPT | Maintain | Neutral (N/A) |
|
Details | ||
| 12/14/2020 | Alexion Pharmaceuticals | ALXN | Downgrade | Neutral (Outperform) |
118.87 (182.01) |
53.12% | Details | |
| 12/10/2020 | CureVac | CVAC | Downgrade | Underperform (Neutral) |
130.05 (4.66) |
-96.42% | Details | |
| 11/13/2020 | Stoke Therapeutics | STOK | Maintain | Outperform (N/A) |
|
Details | ||
| 11/12/2020 | Inhibrx Inc. | INBX | Maintain | Outperform (N/A) |
|
Details | ||
| 11/10/2020 | CureVac | CVAC | Maintain | Neutral (N/A) |
|
Details | ||
| 11/10/2020 | Esperion Therapeutics | ESPR | Upgrade | Outperform (Neutral) |
27.76 (3.18) |
-88.54% | Details | |
| 11/9/2020 | ALX Oncology | ALXO | Maintain | Outperform (N/A) |
|
Details | ||
| 11/6/2020 | Entasis Therapeutics | ETTX | Maintain | Outperform (N/A) |
|
Details | ||
| 11/6/2020 | Ironwood Pharmaceuticals | IRWD | Maintain | Neutral (N/A) |
|
Details | ||
| 11/5/2020 | Intellia Therapeutics | NTLA | Maintain | Neutral (N/A) |
|
Details | ||
| 11/3/2020 | Spruce Biosciences, Inc. | SPRB | New Coverage | Outperform (N/A) |
21.89 (51.58) |
135.63% | Details | |
| 10/30/2020 | PTC Therapeutics | PTCT | Maintain | Neutral (N/A) |
|
Details | ||
| 10/28/2020 | United Therapeutics Corp. | UTHR | Maintain | Outperform (N/A) |
|
Details | ||
| 10/21/2020 | CureVac | CVAC | Maintain | Neutral (N/A) |
|
Details | ||
| 10/7/2020 | Stoke Therapeutics | STOK | Maintain | Outperform (N/A) |
|
Details | ||
| 10/6/2020 | MyoKardia | MYOK | Downgrade | Neutral (Outperform) |
139.60 (224.91) |
61.11% | Details | |
| 9/29/2020 | Sarepta Therapeutics | SRPT | Maintain | Neutral (N/A) |
|
Details | ||
| 9/23/2020 | Insmed | INSM | Maintain | Outperform (N/A) |
|
Details | ||
| 9/14/2020 | Inhibrx Inc. | INBX | New Coverage | Outperform (N/A) |
17.10 (103.63) |
506.02% | Details | |
| 9/8/2020 | CureVac | CVAC | New Coverage | Neutral (N/A) |
56.92 (4.66) |
-91.81% | Details | |
| 8/20/2020 | Sarepta Therapeutics | SRPT | Downgrade | Neutral (Outperform) |
159.04 (18.79) |
-88.19% | Details | |
| 8/19/2020 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Outperform (N/A) |
|
Details | ||
| 8/11/2020 | Esperion Therapeutics | ESPR | Downgrade | Neutral (Outperform) |
38.00 (27.76) |
-26.95% | Details | |
| 8/11/2020 | ALX Oncology | ALXO | New Coverage | Outperform (N/A) |
44.19 (2.04) |
-95.38% | Details | |
| 8/10/2020 | PTC Therapeutics | PTCT | Maintain | Neutral (N/A) |
|
Details | ||
| 8/7/2020 | Acceleron Pharma | XLRN | Maintain | Outperform (N/A) |
|
Details | ||
| 7/29/2020 | Flexion Therapeutics | FLXN | New Coverage | Outperform (N/A) |
12.49 (24.93) |
99.6% | Details | |
| 7/20/2020 | PTC Therapeutics | PTCT | Downgrade | Neutral (Outperform) |
55.70 (69.82) |
25.35% | Details | |
| 7/7/2020 | Kura Oncology | KURA | New Coverage | Outperform (N/A) |
16.72 (11.89) |
-28.89% | Details | |
| 7/7/2020 | Avidity Biosciences | RNA | Maintain | Outperform (N/A) |
|
Details | ||
| 7/1/2020 | Ultragenyx Pharma | RARE | Maintain | Neutral (N/A) |
|
Details | ||
| 6/29/2020 | Esperion Therapeutics | ESPR | Maintain | Outperform (N/A) |
|
Details | ||
| 6/25/2020 | United Therapeutics Corp. | UTHR | Maintain | Outperform (N/A) |
|
Details | ||
| 6/25/2020 | Acceleron Pharma | XLRN | Maintain | Outperform (N/A) |
|
Details | ||
| 6/9/2020 | Esperion Therapeutics | ESPR | Maintain | Outperform (N/A) |
|
Details | ||
| 6/2/2020 | Intellia Therapeutics | NTLA | Maintain | Neutral (N/A) |
|
Details | ||
| 6/1/2020 | Ironwood Pharmaceuticals | IRWD | Maintain | Neutral (N/A) |
|
Details | ||
| 6/1/2020 | Alexion Pharmaceuticals | ALXN | Maintain | Outperform (N/A) |
|
Details | ||
| 5/11/2020 | MyoKardia | MYOK | Maintain | Outperform (N/A) |
|
Details | ||
| 5/8/2020 | Acceleron Pharma | XLRN | Maintain | Outperform (N/A) |
|
Details | ||
| 5/7/2020 | AnaptysBio | ANAB | Maintain | Neutral (N/A) |
|
Details | ||
| 3/17/2020 | Insmed | INSM | Maintain | Outperform (N/A) |
|
Details | ||
| 2/28/2020 | Esperion Therapeutics | ESPR | Maintain | Outperform (N/A) |
|
Details | ||
| 2/14/2020 | Ironwood Pharmaceuticals | IRWD | Maintain | Neutral (N/A) |
|
Details | ||
| 2/13/2020 | United Therapeutics Corp. | UTHR | Maintain | Outperform (N/A) |
|
Details | ||
| 2/11/2020 | MyoKardia | MYOK | Maintain | Outperform (N/A) |
|
Details | ||
| 2/3/2020 | Insmed | INSM | Maintain | Outperform (N/A) |
|
Details | ||
| 1/28/2020 | Acceleron Pharma | XLRN | Maintain | Outperform (N/A) |
|
Details | ||
| 1/14/2020 | Sarepta Therapeutics | SRPT | Maintain | Outperform (N/A) |
|
Details | ||
| 1/8/2020 | Arena Pharma | ARNA | Maintain | Outperform (N/A) |
|
Details | ||
| 12/13/2019 | Sarepta Therapeutics | SRPT | Maintain | Outperform (N/A) |
|
Details | ||
| 12/10/2019 | Forty Seven Inc. | FTSV | Maintain | Outperform (N/A) |
|
Details | ||
| 12/5/2019 | Forty Seven Inc. | FTSV | Maintain | Outperform (N/A) |
|
Details | ||
| 11/13/2019 | PTC Therapeutics | PTCT | Maintain | Outperform (N/A) |
|
Details | ||
| 11/8/2019 | Sarepta Therapeutics | SRPT | Maintain | Outperform (N/A) |
|
Details | ||
| 11/8/2019 | ObsEva | OBSV | Downgrade | Neutral (Outperform) |
7.94 (0.10) |
-98.74% | Details | |
| 11/6/2019 | Ultragenyx Pharma | RARE | Maintain | Neutral (N/A) |
|
Details | ||
| 11/5/2019 | uniQure BV | QURE | New Coverage | Outperform (N/A) |
51.38 (48.37) |
-5.86% | Details | |
| 10/3/2019 | AnaptysBio | ANAB | Maintain | Neutral (N/A) |
|
Details | ||
| 8/26/2019 | Acceleron Pharma | XLRN | Maintain | Outperform (N/A) |
|
Details | ||
| 8/20/2019 | Sarepta Therapeutics | SRPT | Maintain | Outperform (N/A) |
|
Details | ||
| 8/9/2019 | AnaptysBio | ANAB | Maintain | Neutral (N/A) |
|
Details | ||
| 7/29/2019 | ObsEva | OBSV | Maintain | Outperform (N/A) |
|
Details | ||
| 7/15/2019 | Stoke Therapeutics | STOK | New Coverage | Outperform (N/A) |
27.85 (32.29) |
15.94% | Details | |
| 7/1/2019 | United Therapeutics Corp. | UTHR | Upgrade | Outperform (Neutral) |
77.01 (513.12) |
566.3% | Details | |
| 6/21/2019 | AnaptysBio | ANAB | Downgrade | Neutral (Outperform) |
66.56 (57.74) |
-13.25% | Details | |
| 6/7/2019 | MyoKardia | MYOK | Maintain | Outperform (N/A) |
|
Details | ||
| 5/28/2019 | BioMarin Pharmaceutical Inc. | BMRN | Maintain | Outperform (N/A) |
|
Details | ||
| 5/9/2019 | United Therapeutics Corp. | UTHR | Upgrade | Neutral (Underperform) |
99.49 (77.01) |
-22.6% | Details | |
| 5/6/2019 | Esperion Therapeutics | ESPR | Maintain | Outperform (N/A) |
|
Details | ||
| 3/26/2019 | United Therapeutics Corp. | UTHR | Maintain | Underperform (N/A) |
|
Details | ||
| 3/11/2019 | Sarepta Therapeutics | SRPT | Maintain | Outperform (N/A) |
|
Details | ||
| 2/27/2019 | Arena Pharma | ARNA | Maintain | Outperform (N/A) |
|
Details | ||
| 2/27/2019 | Arena Pharma | ARNA | Maintain | Outperform (N/A) |
|
Details | ||
| 2/11/2019 | Sarepta Therapeutics | SRPT | Maintain | Outperform (N/A) |
|
Details | ||
| 1/29/2019 | PTC Therapeutics | PTCT | Maintain | Outperform (N/A) |
|
Details | ||
| 1/28/2019 | Alexion Pharmaceuticals | ALXN | Maintain | Outperform (N/A) |
|
Details | ||
| 1/22/2019 | Alexion Pharmaceuticals | ALXN | Maintain | Outperform (N/A) |
|
Details | ||
| 1/4/2019 | MyoKardia | MYOK | Maintain | Outperform (N/A) |
|
Details | ||
| 11/19/2018 | United Therapeutics Corp. | UTHR | Maintain | Underperform (N/A) |
|
Details | ||
| 11/19/2018 | Arena Pharma | ARNA | Maintain | Outperform (N/A) |
|
Details | ||
| 11/16/2018 | Spark Therapeutics | ONCE | Upgrade | Neutral (Underperform) |
40.81 (110.05) |
169.66% | Details | |
| 11/9/2018 | AnaptysBio | ANAB | Maintain | Outperform (N/A) |
|
Details | ||
| 10/29/2018 | Ultragenyx Pharma | RARE | Maintain | Neutral (N/A) |
|
Details | ||
| 10/29/2018 | Intellia Therapeutics | NTLA | New Coverage | Neutral (N/A) |
20.00 (12.84) |
-35.8% | Details | |
| 10/22/2018 | Entasis Therapeutics | ETTX | New Coverage | Outperform (N/A) |
7.44 (2.19) |
-70.56% | Details | |
| 10/19/2018 | Ra Pharma | RARX | Maintain | Outperform (N/A) |
|
Details | ||
| 10/3/2018 | PTC Therapeutics | PTCT | Maintain | Outperform (N/A) |
|
Details | ||
| 10/1/2018 | Insmed | INSM | Maintain | Outperform (Outperform) |
|
Details | ||
| 9/27/2018 | AnaptysBio | ANAB | Maintain | Outperform (N/A) |
|
Details | ||
| 9/25/2018 | Alexion Pharmaceuticals | ALXN | Maintain | Outperform (N/A) |
|
Details | ||
| 9/6/2018 | Sarepta Therapeutics | SRPT | New Coverage | Outperform (N/A) |
143.45 (18.79) |
-86.9% | Details | |
| 9/5/2018 | PTC Therapeutics | PTCT | Maintain | Outperform (N/A) |
|
Details |
